Proinflammatory biomarkers and platelet aggregation activity in patients with coronary artery disease

Abstract

Aim. To determine concentrations and identify the relationship of biomarkers (endocan / cell-specific molecule-1, fatty acid binding protein 4 (FABP 4), placental growth factor (PlGF), oncostatin M), with parameters of collageninduced platelet aggregation in patients with coronary artery disease (CAD).Materials and methods. In patients with CAD (n = 51), serum levels of endocan, FABP 4, PlGF, oncostatin M, and platelet aggregation indices (collagen at concentrations of 2 and 10 mmol / l) were determined. Patients were divided into groups with and without high residual platelet reactivity (HRPR). Correlation coefficients between concentrations of proinflammatory biomarkers and platelet aggregation indices were determined in patients of both groups.Results. In patients with HRPR, the concentrations of endocan and PlGF were significantly higher, and the concentrations of FABP4 and oncostatin M were lower than in the first group. In patients with HRPR, a correlation was found between the concentration of endocan and the degree of platelet aggregation in the presence of 2 mmol/ l of collagen (ρ = 0.48; p = 0.01), between the concentration of PlGF and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.58; p = 0.01), as well as between the concentration of FABP 4 and the size of aggregates at both collagen concentrations (ρ = 0.42; p = 0.03) and (ρ = 0.70; p = 0.01) and the degree of platelet aggregation in the presence of 10 mmol / l of collagen (ρ = 0.43; p = 0.01).Conclusion. In all examined CAD patients, regardless of the residual platelet reactivity, the levels of endocan and FABP 4 increased compared to the reference values. In patients with HRPR, the content of parameters (endocan, PlGF) contributing to plaque growth was elevated, and in patients without HRPR, the levels of platelet-activating factors (FABР 4, oncostatin M) were increased, which determines a personalized approach to prescribing therapy for these groups of patients. In patients with CAD, platelet aggregation indices were associated with concentrations of proinflammatory biomarkers (endocan, PlGF, and FABP 4), which contribute to the development of endothelial dysfunction.